Citeline, Biomedtracker: see the drug development process th...
Catch up on any missed COVID-19 24 hour webinar sessions
December 1 is World AIDS Day, dedicated to raising awareness of the worldwide AIDS pandemic caused by the spread of HIV infection. To commemorate the occasion, Informa Pharma Intelligence is offering a free download of the GlaxoSmithKline: Company Analysis report extract from Datamonitor Healthcare.
In it, PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2017–27, which is highly dependent on successful uptake of two-drug regimens in HIV such as Juluca, cabotegravir/rilpivirine, and Tivicay/Epivir to drive growth.
The GlaxoSmithKline: Company Analysis extract contains vital information about GSK’s Q2 2018 review, including:
Datamonitor Healthcare: data analysis and insight, Pink Shee...
By Tara Hansen
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.
Datamonitor Healthcare: data analysis and insight
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: